Your browser doesn't support javascript.
loading
Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets.
Oh, Han Na; Shin, Seung Yong; Kim, Jong-Hwa; Baek, Jihye; Kim, Hyo Jong; Lee, Kang-Moon; Park, Soo Jung; Kim, Seok-Young; Choi, Hyung-Kyoon; Kim, Wonyong; Sul, Woo Jun; Choi, Chang Hwan.
Afiliación
  • Oh HN; Department of Systems Biotechnology, Chung-Ang University, Anseong, 17546, Republic of Korea.
  • Shin SY; Inflamm-Aging Translational Research Center, Ajou University Medical Center, Suwon, Republic of Korea.
  • Kim JH; Department of Internal Medicine, Chung-Ang University College of Medicine, 102 Heukseok-Ro, Dongjak-Gu, Seoul, Republic of Korea, 06973.
  • Baek J; Department of Microbiology, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
  • Kim HJ; Department of Microbiology, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
  • Lee KM; Department of Gastroenterology, Kyung Hee University Hospital, Seoul, Republic of Korea.
  • Park SJ; Department of Gastroenterology, The Catholic University of Korea St. Vincent's Hospital, Suwon, Republic of Korea.
  • Kim SY; Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Choi HK; College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
  • Kim W; College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
  • Sul WJ; Department of Microbiology, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
  • Choi CH; Department of Systems Biotechnology, Chung-Ang University, Anseong, 17546, Republic of Korea. sulwj@cau.ac.kr.
Gut Pathog ; 16(1): 44, 2024 Aug 26.
Article en En | MEDLINE | ID: mdl-39187879
ABSTRACT

BACKGROUND:

While significant research exists on gut microbiota changes after anti-tumor necrosis factor-alpha (anti TNF-α) therapy for ulcerative colitis, little is known about the longitudinal changes related to the effects of anti TNF-α. This study aimed to investigate the dynamics of gut microbiome changes during anti TNF-α (adalimumab) therapy in patients with ulcerative colitis (UC).

RESULTS:

The microbiota composition was affected by the disease severity and extent in patients with UC. Regardless of clinical remission status at each time point, patients with UC exhibited microbial community distinctions from healthy controls. Distinct amplicon sequence variants (ASVs) differences were identified throughout the course of Adalimumab (ADA) treatment at each time point. A notable reduction in gut microbiome dissimilarity was observed only in remitters. Remitters demonstrated a decrease in the relative abundances of Burkholderia-Caballeronia-Paraburkholderia and Staphylococcus as the treatment progressed. Additionally, there was an observed increase in the relative abundances of Bifidobacterium and Dorea. Given the distribution of the 48 ASVs with high or low relative abundances in the pre-treatment samples according to clinical remission at week 8, a clinical remission at week 8 with a sensitivity and specificity of 72.4% and 84.3%, respectively, was predicted on the receiver operating characteristic curve (area under the curve, 0.851).

CONCLUSIONS:

The gut microbiota undergoes diverse changes according to the treatment response during ADA treatment. These changes provide insights into predicting treatment responses to ADA and offer new therapeutic targets for UC.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Gut Pathog Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Gut Pathog Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido